The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis
- PMID: 384931
- PMCID: PMC1000446
- DOI: 10.1136/ard.38.3.248
The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis
Abstract
In 1964 Nienhuis and Mandema reported the presence of antibodies against cytoplasmic granules in buccal mucosal cells in the serum of 50% of patients with rheumatoid arthritis (RA). Although they reported a good specificity for RA of these so-called antiperinuclear antibodies (APF), their results never threatened the monopoly of the rheumatoid factor as a serological tool for the diagnosis of RA. A re-evaluation with improved immunofluorescence methods showed a frequency of the APF of 78% in 103 patients with RA. The latex test and the Waaler-Rose test were positive in only 70% and 58% respectively of these patients. Only 15% of the RA patients were negative for all 3 tests. Thus, 40% of patients who were seronegative by the traditional methods gave a positive result on performance of the APF test. The high sensitivity of the APF test was combined with a good specificity, for the frequency in patients with other autoimmune diseases or degenerative joint disease and in healthy subjects was low. For the serodiagnosis of RA it seems best to combine the use of the APF test with one for rheumatoid factor.
Similar articles
-
Specificity of antiperinuclear factor for rheumatoid arthritis in rheumatoid factor-positive sera.Br J Rheumatol. 1995 Aug;34(8):716-20. doi: 10.1093/rheumatology/34.8.716. Br J Rheumatol. 1995. PMID: 7551653
-
Antiperinuclear factor in an Italian series of patients with rheumatoid arthritis.Ric Clin Lab. 1983 Jul-Sep;13(3):347-52. doi: 10.1007/BF02905878. Ric Clin Lab. 1983. PMID: 6606208
-
The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis.J Rheumatol. 1988 Sep;15(9):1346-50. J Rheumatol. 1988. PMID: 3058971
-
Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications.Semin Arthritis Rheum. 1994 Jun;23(6):379-87. doi: 10.1016/0049-0172(94)90088-4. Semin Arthritis Rheum. 1994. PMID: 7524151 Review.
-
The antiperinuclear factor and antikeratin antibody systems.Int Arch Allergy Immunol. 1995 Aug;107(4):508-18. doi: 10.1159/000237093. Int Arch Allergy Immunol. 1995. PMID: 7542514 Review.
Cited by
-
Potential protein targets of the peptidylarginine deiminase 2 and peptidylarginine deiminase 4 enzymes in rheumatoid synovial tissue and its possible meaning.Eur J Rheumatol. 2016 Jun;3(2):44-49. doi: 10.5152/eurjrheum.2015.0055. Epub 2016 Feb 1. Eur J Rheumatol. 2016. PMID: 27708970 Free PMC article.
-
The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.J Clin Invest. 1995 Jun;95(6):2672-9. doi: 10.1172/JCI117969. J Clin Invest. 1995. PMID: 7539459 Free PMC article.
-
Antiperinuclear activity in lung carcinoma patients.Cancer Immunol Immunother. 1984;18(2):80-1. doi: 10.1007/BF00205738. Cancer Immunol Immunother. 1984. PMID: 6334550 Free PMC article.
-
Clinical relevance of antikeratin antibodies in rheumatoid arthritis.Clin Rheumatol. 1982 Sep;1(3):185-9. doi: 10.1007/BF02042772. Clin Rheumatol. 1982. PMID: 6205812
-
Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin.Ann Rheum Dis. 1991 Sep;50(9):611-8. doi: 10.1136/ard.50.9.611. Ann Rheum Dis. 1991. PMID: 1718228 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources